Xencor, Inc. (XNCR)

In the past six months, Xencor's stock has trended up, but over the past year, it experienced a decline. Recent events include the outlining of corporate priorities and pipeline milestones in January 2026, which led to a share price decrease. Analyst price targets were adjusted, with BofA raising its target. Insider selling occurred in December 2025. The company reported its Q3 2025 earnings with a net loss, but the reported EPS beat analyst estimates. Several analysts updated their ratings and price objectives in November 2025. In August 2025, Xencor reported Q2 2025 revenue exceeding analyst estimates. As of January 13, 2026, Xencor's shares passed below its 50-day moving average.

Direct demand seasonality is not applicable to Xencor, Inc.'s products and services. Revenue is primarily generated through strategic partnerships, licensing agreements, milestone payments, and royalties from partnered products. The demand for its pipeline candidates or technology platform is driven by clinical trial progress, regulatory approvals, and partners' strategic decisions, rather than seasonal consumer patterns. Stock market seasonality refers to stock market seasonality and not to the demand for its biopharmaceutical products or services.

Xencor, Inc. is a clinical-stage biopharmaceutical company focused on developing engineered monoclonal antibodies and protein therapeutics using its XmAb® technology platform. They aim to create therapies for severe diseases like cancer, autoimmune diseases, asthma, and allergic diseases. Their pipeline includes wholly-owned programs such as Vudalimab, XmAb819, XmAb808, XmAb541, XmAb942, Obexelimab, and XmAb657, each in various phases of clinical trials. Xencor also has partnered programs like Ultomiris, Monjuvi, and Sotrovimab, along with other partnered candidates like Xaluritamig, ASP2138, JNJ-9401, and JNJ-1493.

Xencor, Inc. is headquartered in Pasadena, California, United States. Its stock is traded on the Nasdaq Global Market (NasdaqGM: XNCR) and listed on European exchanges including Munich, Stuttgart, Frankfurt, and Berne. The shareholder base is mainly in the United States, with some institutional ownership from the United Kingdom, Australia, and Canada.

Xencor maintains a generally positive brand reputation within the financial and biotechnology communities, reflected in analyst sentiment and industry standing. The company has a consensus rating of "Moderate Buy" from analysts. Events affecting its reputation are tied to clinical development progress and financial performance. Positive clinical data and strong financial results contribute positively, while stock price declines can temporarily impact investor perception. There is no information indicating major negative events that have significantly damaged Xencor's brand reputation beyond the inherent risks of biotech drug development.

The ownership of Xencor, Inc. is primarily distributed among institutional investors, mutual funds, and individual shareholders. Major institutional owners include BlackRock, Inc., Primecap Management Co/ca/, Vanguard Group Inc, RTW Investments, Lp, EcoR1 Capital, LLC, State Street Corp, BVF Inc/il, and Renaissance Technologies LLC. The founders, Dr. Bassil Dahiyat and Dr. Stephen Mayo, also retain ownership stakes. Institutional ownership is substantial, indicating strong belief in Xencor's XmAb technology.